RT Journal Article
SR Electronic
T1 Two advances in the management of Parkinson disease
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 639
OP 643
VO 69
IS 8
A1 Erwin B. Montgomery, Jr.
YR 2002
UL http://www.ccjm.org/content/69/8/639.abstract
AB Levodopa should generally be avoided early in the course of Parkinson disease; dopamine agonists, particularly second-generation agents such as ropinirole (Requip) and pramipexole (Mirapex), carry a smaller long-term risk of dyskinesia and should be used instead. Deep brain stimulation is remarkably effective in refractory cases and may well usher in a new era in the treatment of chronic neurologic disease.